Tryp Therapeutics Announces Formation of Psilocybin Scientific Advisory Board



Ryan Allway

October 9th, 2020

Psychedelics


Tryp Therapeutics Inc. (“Tryp” or the “Company“), a pharmaceutical company developing therapeutics specifically targeting diseases with high unmet medical needs announced today the formation of a Scientific Advisory Board (“SAB“) for its Psilocybin For Neuropsychiatry (“PFN™“) program. The PFN™ SAB is a preeminent group of experts in neuropsychiatry research and clinical care specifically chosen to advise on the Company’s TRP-8802, TRP-8803 and TRP-8804 investigational drugs.

Tryp has entered into consulting agreements with Dr. Rachel Wevrick, PhD, of University of Alberta, and Dr. Derek Ott, MD, MS, of University of California, Los Angeles (UCLA) School of Medicine. Dr. Wevrick is Professor, Department of Medical Genetics, at University of Alberta. Her research is focused on the genetic, molecular, and physiological basis of abnormal neurodevelopment, growth and metabolism in developmental disorders affecting children. Her specific areas of interest include: Prader-Willi syndrome (“PWS“) and Translational research in PWS, Schaaf-Yang syndrome, and other neurodevelopmental disabilities that are caused by de novo or inherited genetic mutations that affect the function of the brain and nervous system including Bardet-Biedl syndrome, Tourette syndrome, and severe early onset obesity with intellectual disability. She earned her PhD from the Department of Molecular and Medical Genetics, University of Toronto and completed post-doctoral fellowships in the Department of Genetics at The Hospital for Sick Children Research Institute, and at Howard Hughes Medical Institute, Stanford University School of Medicine.

Dr. Derek Ott is associate clinical professor of psychiatry at UCLA School of Medicine, the director of the UCLA Pediatric Neuropsychiatry Clinic and a psychiatric consultant for Westside and Frank D Lanterman Regional Centers in Los Angeles. He is board certified physician in in both child and adolescent as well as adult psychiatry. Dr. Ott graduated from Stanford University with honors and a degree in human biology. He then attended the University of Illinois in Urbana-Champaign, where he completed his medical and graduate training (Masters in Neuroscience). Dr. Ott began his clinical training in psychiatry at the University of California-Los Angeles Resnick Neuropsychiatric Hospital in Westwood, where he completed a residency in Adult Psychiatry , as well as a fellowship in Child and Adolescent Psychiatry. Following this clinical training, Dr. Ott participated in a NIMH sponsored post-doctoral fellowship which focused on psychopathology in pediatric epilepsy. Dr. Ott has particular expertise in the areas of neuropsychiatry, developmental disabilities, attention-deficit hyperactivity disorder and childhood psychosis. He has extensive experience working with individuals with neurological disorders, developmental disabilities (i.e. autism and intellectual disability), as well as comorbid behavioral/psychiatric disorder. His private practice focuses on psychopharmacology in children, adolescents, and adults.

“Working with Drs. Wevrick and Ott fulfill a critical component of our development strategy focused on accelerating psilocybin clinical testing. We are very pleased to have two such well recognized key opinion leaders support our PFN™ program. By working with them, we are able to design the optimal drug development pathway for fibromyalgia and Prader-Willi Syndrome,” said Tom D’Orazio, Chief Operating Officer of Tryp.

About Tryp Therapeutics:

Tryp Therapeutics is an early stage pharmaceutical development company led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The Company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Latest posts